Consensus on integrated care of acute exacerbations of chronic obstructive pulmonary disease (ATINA-EPOC). Part VI;Consenso sobre atención integral de las agudizaciones de la enfermedad pulmonar obstructiva crónica (ATINA-EPOC). Parte VI

Semergen

Volumn 39, Issue 2, 2013, Pages 85-88

  Arnedillo Munoz A ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSENSUS DEVELOPMENT; DISEASE COURSE; HUMAN; INTEGRATED HEALTH CARE SYSTEM;

ACUTE DISEASE; DELIVERY OF HEALTH CARE, INTEGRATED; DISEASE PROGRESSION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84875376010     PISSN: 11383593     EISSN: 15788865     Source Type: Journal    
DOI: 10.1016/j.semerg.2012.04.006     Document Type: Article

References (18)

1. Appleton S., Poole P., Smith B., Veale A., Lasserson T.J., Chan M.M. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006, 3:CD001104.
2. Puhan M.A., Bachmann L.M., Kleijnen J., Ter Riet G., Kessels A.G. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med 2009, 7:2.
3. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
4. Vogelmeier C., Hederer B., Glaab T., Schmidt H., Rutten-van Mölken M.P., Beeh K.M., et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011, 364:1093-1103.
5. Yang I.A., Fong K.M., Sim E.H., Black P.N., Lasserson T.J. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007, CD002991.
6. Mills E.J., Druyts E., Ghement I., Puhan M.A. Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol 2011, 3:107-129.
7. Rennard S.I., Calverley P.M., Goehring U.M., Bredenbröker D., Martinez F.J. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res 2011, 12:18.
8. Nannini L.J., Cates C.J., Lasserson T.J., Poole P. Combined corticosteroid and longacting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007, CD006829.
9. Aaron S.D., Vandemheen K.L., Fergusson D., Maltais F., Bourbeau J., Goldstein R., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Ann Intern Med 2007, 146:545-555.
10. Welte T., Miravitlles M., Hernandez P., Eriksson G., Peterson S., Polanowski T., et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:741-750.
11. Poole P.J., Black P.N. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006, 3:CD001287.
12. Zheng J.P., Kang J., Huang S.G. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebocontrolled study. Lancet 2008, 371:2013-2018.
13. Poole P.J., Chacko E., Wood-Baker R.W., Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006, CD002733.
14. Alfageme I., Vazquez R., Reyes N., Muñoz J., Fernández A., Hernandez M., et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006, 61:189-195.
15. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important?. Eur Respir J 2002, 36(Suppl):S9-S19.
16. Puhan M., Scharplatz M., Troosters T., Walters E.H., Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Data base Syst Rev 2009, CD005305.
17. Wagena E.J., Zeegers M.P.A., Van Schayck C.P., Wouters E.F.M. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Saf 2003, 26:381-403.
18. Simmons M.S., Connett J.E., Nides M.A., Lindgren P.G., Kleerup E.C., Murray R.P., et al. Smoking reduction and the rate of decline in FEV1: results from the Lung Health Study. Eur Respir J 2005, 25:1011-1017.